EHA 2018 Multiple Myeloma Abstracts –
Oral Presentations
Oral presentations of multiple myeloma-related research findings will take place on three main days of the 2015 European Hematology Association (EHA) annual meeting – Friday, June 15; Saturday, June 16; and Sunday, June 17.
The list below contains the titles and authors of all multiple myeloma oral presentations at EHA 2018. Presenter names are in bold.
The list is organized in chronological order by session. Each entry in the list also includes a link to the full text of the relevant abstract at the EHA website.
Most of the presentations take place during sessions focused on multiple myeloma, but there are some presentations in the list from sessions on other topics, such as stem cell transplantation.
Links to PDF files containing presentation slides will be added to entries in this list as those files are made available to The Beacon courtesy of the EHA presenters.
Please note that this list is oral presentations focused on original research. It does not include presentations that will be given during education sessions, symposia, or debates.
The Beacon also has three lists of the myeloma-related posters from the 2018 EHA meeting. There is one list for the posters to be presented on Friday, June 15; a second list for the posters to be presented on Saturday, June 16; and a third list for myeloma-related e-posters.
| Session | Advances in Front-Line Treatment of Newly Diagnosed Multiple Myeloma |
| Type | Oral Presentation Session |
| Time | Friday June 15, 11:30 AM to 12:45 PM |
| Location | Victoria Hall |
| Chairs | A Larocca and F Schjesvold |
S105 – A Triplet Bortezomib- And Immunomodulator-Based Therapy Before And After Double ASCT Improves Overall Survival Of Newly Diagnosed MM Patients: Final Analysis Of Phase 3 GIMEMA-MMY-3006 Study
11:30 AM - 11:45 AM
Paola Tacchetti, Francesca Patriarca, Maria Teresa Petrucci, Monica Galli, Lucia Pantani, Luca Dozza, Francesco Di Raimondo, Mario Boccadoro, Massimo Offidani, Vittorio Montefusco, Norbert Pescosta, Antonio Ledda, Tommaso Caravita, Nicola Cascavilla, Barbara Gamberi, Piero Maria Stefani, Carolina Terragna, Giulia Marzocchi, Felicetto Ferrara, Valerio De Stefano, Elena Zamagni, Michele Cavo (abstract)
S106 – Autologous Stem Cell Transplantation Is Safe And Effective For Older Myeloma Patients: Results From The Myeloma XI Trial
11:45 AM - 12:00 PM
Charlotte Pawlyn, Faith Davies, Alina Striha, David Cairns, John Jones, Bhuvan Kishore, Mamta Garg, Cathy Williams, Kamaraj Karunanithi, Jindriska Lindsay, Matthew Jenner, Gordon Cook, Nigel Russell, Mark Drayson, Martin Kaiser, Roger Owen, Walter Gregory, Gareth Morgan, Graham Jackson (abstract)
S107 – Daratumumab Plus Bortezomib-Melphalan-Prednisone (VMP) In Elderly (≥75 Years Of Age) Patients With Newly Diagnosed Multiple Myeloma Ineligible For Transplantation (ALCYONE)
12:00 PM - 12:15 PM
Jesus San-Miguel, Shinsuke Iida, Joan Blade, Maria-Victoria Mateos, Je-Jung Lee, Mamta Garg, Vania Hungria, Meral Beksac, Ivan Spicka, Stefan Knop, Ludek Pour, Philip Campbell, Andrzej Jakubowiak, Michael K. Bauer, Jim Wang, Susan Wroblewski, Rachel Kobos, Ming Qi, Michele Cavo (abstract)
S108 – Consolidation Followed By Maintenance Vs Maintenance Alone In Newly Diagnosed, Transplant Eligible Multiple Myeloma: A Randomized Phase 3 Study Of The European Myeloma Network (EMN02 / HOVON-95 MM Trial)
12:15 PM - 12:30 PM
P Sonneveld, M Beksac, B vanderHolt, MA Dimopoulos, A Carella, H Ludwig, C Driessen, R Wester, R Hajek, P Cornelisse, R Troia, L Dozza, F Gay, A Cafro, L De Rosa, G Fiontoni, G Fiontoni, UH Mellqvist, HE Johnsen, S Zweegman, KL Wu, J Parreira, FH Schjesvold, J D'Rozario, AP Palumbo, M Boccadoro, M Cavo (abstract)
S109 – Updated Efficacy And MRD Data According To Risk-status In Newly Diagnosed Myeloma Patients Treated With Carfilzomib Plus Lenalidomide Or Cyclophosphamide: Results From The FORTE Trial
12:30 PM - 12:45 PM
Francesca Gay, Delia Rota Scalabrini, Angelo Belotti, Stefania Oliva, Alessandro Rambaldi, Elena Zamagni, Massimo Offidani, Paola Omedé, Chiara Cerrato, Rossella Troia, Alessandro Gozzetti, Giuseppe Pietrantuono, Vincenzo Pavone, Luca De Rosa, Salvatore Palmieri, Franco Narni, Anna Pascarella, Renato Zambello, Vittorio Montefusco, Antonio Palumbo, Pellegrino Musto, Michele Cavo, Mario Boccadoro (abstract)
| Session | Stem Cell Transplantation – Clinical 1 |
| Type | Oral Presentation Session |
| Time | Friday June 15, 11:30 AM to 12:45 PM |
| Location | Room A6 |
| Chairs | A Spyridonidis and J Sierra |
S124 – Busulfan + Melphalan Was Associated With A Longer PFS Compared To Melphalan Alone In High-Risk Multiple Myeloma In A Randomized Phase 3 Clinical Trial
11:30 AM - 12:00 PM
Muzaffar Qazilbash, Qaiser Bashir, Peter Thall, Denai Milton, Nina Shah, Krina Patel, Borje Andersson, Yago Nieto, Partow Kebriaei, Ben Valdez, Jitesh Kawedia, Simrit Parmar, Ruby Delgado, Sairah Ahmed, Chitra Hosing, Uday Popat, Elizabeth Shpall, Donna Weber, Sheeba Thomas, Elisabet Manasanch, Hans Lee, Robert Orlowski, Richard Champlin (abstract)
S126 – The Impact Of Recipient Age On Allogeneic Stem Cell Transplantation Outcome – A Comparison Between Siblings Versus Unrelated Versus Alternative Donors: An Analysis On Behalf Of The ALWP Of The EBMT
12:00 PM - 12:15 PM
Roni Shouval, Joshua Fein, Myriam Labopin, Nicolaus Kröger, Rafael F. Duarte, Peter Bader, Chiara Bonini, Jurgen Kuball, Grzegorz Basak, Carlo Dufour, Arjan Lankester, Silvia Montoto, John A Snowden, Jan Styczynski, Mohamad Mohty, Arnon Nagler (abstract)
| Session | Gene Therapy, Cellular Immunotherapy and Vaccination - Biology & Translational Research |
| Type | Oral Presentation Session |
| Time | Friday June 15, 11:30 AM - 12:45 PM |
| Location | Room A8 |
| Chairs | A Van de Loosdrecht and M Subklewe |
S134 – Pre-clinical Results Of A Humanized CART-BCMA For Multiple Myeloma Patients
11:30 AM - 12:00 PM
Lorena Pérez-Amill, Guillermo Suñe, Maria Castella Castella, Amer Najjar, Manel Juan, Carlos Fernández-de Larrea, Alvaro Urbano-Ispizua, Beatriz Martín-Antonio (abstract)
S136 – P53 Isoform D133P53A: A New Transcriptional Enhancer of T-Cell Effector Function
12:00 PM - 12:15 PM
Kevin Legscha, Edite Antunes, Eva Amann, Borhane Guezguez, Matthias Theobald, Hakim Echchannaoui (abstract)
S138 – BB2121 Anti-BCMA CAR T Cell Therapy In Patients With Relapsed / Refractory Multiple Myeloma: Updated Results From A Multicenter Phase 1 Study
12:30 PM - 12:45PM
Noopur Raje, Jesus Berdeja, Yi Lin, Nikhil Munshi, David Siegel, Michaela Liedtke, Sundar Jagannath, Deepu Madduri, Jacalyn Rosenblatt, Marcela Maus, Ashley Turka, Lyh Ping Lam, Richard A. Morgan, M. Travis Quigley, Monica Massaro, Kristen Hege, Fabio Petrocca, James M. Kochenderfer (abstract)
| Session | New Therapeutic Strategies to Improve the Outcome of Relapsed / Refractory Plasma Cell Disorders |
| Type | Oral Presentation Session |
| Time | Saturday June 16, 4:00 PM to 5:15 PM |
| Location | Room A1 |
| Chairs | E Ocio and E Zamagni |
S847 – OPTIMISMM: Phase 3 Trial Of Pomalidomide, Bortezomib, And Low‐Dose Dexamethasone vs Bortezomib And Low-Dose Dexamethasone In Lenalidomide-Exposed Patients With Relapsed / Refractory Multiple Myeloma
4:00 PM - 4:15 PM
Paul Richardson, Albert Oriol Rocafiguera, Meral Beksac, Anna Marina Liberati, Monica Galli, Fredrik Schjesvold, Jindriska Lindsay, Katja Weisel, Darrell White, Thierry Facon, Jesus San Miguel, Kazutaka Sunami, Peter O'Gorman, Pieter Sonneveld, Pawel Robak, Sergey Semochkin, Steve Schey, Xin Yu, Thomas Doerr, Amine Bensmaine, Tsvetan Biyukov, Teresa Peluso, Mohamed Zaki, Kenneth Anderson, Meletios Dimopoulos (abstract)
S848 – MOR202 With Low-Dose Dexamethasone (Dex) Or Pomalidomide / Dex Or Lenalidomide / Dex In Relapsed Or Refractory Multiple Myeloma (RRMM): A Phase I/IIa, Multicenter, Dose-Escalation Study
4:15 PM - 4:30 PM
Marc Raab, Manik Chatterjee, Hartmut Goldschmidt, Hermine Agis, Igor W. Blau, Hermann Einsele, Monika Engelhardt, Barbara Ferstl, Martin Gramatzki, Christoph Röllig, Katja Weisel, Tiantom Jarutat, Dominika Weinelt, Mark Winderlich, Rainer Boxhammer, Christian Peschel (abstract)
S849 – Once-Weekly vs Twice-Weekly Carfilzomib Dosing Plus Dexamethasone In Patients With Relapsed And Refractory Multiple Myeloma (RRMM): Results Of The Randomized Phase 3 Study A.R.R.O.W.
4:30 PM - 4:45 PM
Maria-Victoria Mateos, Philippe Moreau, James R. Berenson, Katja Weisel, Antonio Lazzaro, Kevin Song, Meletios A. Dimopoulos, Mei Huang, Anita Zahlten-Kumeli, A. Keith Stewart (abstract)
S850 – Final Results Of A Phase Ib Study Of Isatuximab Plus Pomalidomide And Dexamethasone In Relapsed / Refractory Multiple Myeloma.
4:45 PM - 5:00 PM
Joseph Mikhael, Paul Richardson, Saad Usmani, Noopur Raje, William Bensinger, Chatchada Karanes, Franck Dubin, Qianying Liu, Olivier Vitse, Kenneth Anderson (abstract)
| Session | Biological Insights and Preclinical Studies in Multiple Myeloma |
| Type | Oral Presentation Session |
| Time | Sunday June 17, 8:00 AM to 9:15 AM |
| Location | Room A7 |
| Chairs | C Terragna and H Avet-Loiseau |
S1575 – The Chronological Order Of Copy Number Changes In Hyperdiploid Multiple Myeloma Patients
8:00 AM - 8:15 AM
Francesco Maura, Niccolò Bolli, Kevin Dawson, Nicos Angelopoulos, Raphae Szalat, Inigo Martincorena, Thomas Mitchell, Anthony Fullam, Stephane Minvielle, Santiago Gonzales, Dominik Glodzik, Daniel Leongamornlert, Mehmet Kemal Samur, Mariateresa Fulciniti, Yu Tzu Tai, Florence Magrangeas, Philippe Moreau, Paolo Corradini, Kenneth Anderson, Moritz Gerstung, Herve Avet-Loiseau, Peter Campbell, Nikhil Munshi (abstract)
S1576 – Expression Of Proteins In CD138+ Plasma Cells Predicts Prognosis In Newly Diagnosed Multiple Myeloma Patients Treated With VRD Regimen.
8:15 AM - 8:30 AM
Irena Misiewicz-Krzeminska, Luis Corchete, Isabel Isidro, Teresa Prieto, Vanesa Gutierrez, Elizabeta Rojas, Cristina De Ramon, Joaquin Martinez-Lopez, Ramon Garcia-Sanz, Albert Oriol, Joan Blade, Juan Jose Lahuerta, Jesus San Miguel, Maria-Victoria Mateos, Norma Gutierrez (abstract)
S1577 – Effects Of Daratumumab On The Composition And Activation Status Of Immune-Cell Populations In CENTAURUS, A Phase 2 Randomized Study Of Smoldering Multiple Myeloma (SMM) Patients
8:30 AM - 8:45 AM
Homer Adams III, Koen Van der Borght, Yann Abraham, Greet Vanhoof, Tina Smets, Amy Axel, Stan Gaj, Frederik Stevenaert, Christopher Chiu, C. Ola Landgren, Craig Hofmeister, Hartmut Goldschmidt, Tobias Neff, Ming Qi, Tineke Casneuf (abstract)
S1578 – Simultaneous Targeting Of MCL-1 (S63845) And BCL-2 (Venetoclax) Anti-Apoptotic Proteins In Multiple Myeloma
8:45 AM - 9:00 AM
Esperanza M Algarín, Laura San-segundo, Susana Hernández-García, Lorena González-Méndez, Montserrat Martín-Sánchez, Pedro Mogollón, Andrea Díaz-Tejedor, Marie Schoumacher, Sébastien Banquet, Laurence Kraus-Berthier, Ioana Kloos, Ensar Halilovic, Heiko Maacke, Norma C Gutiérrez, María-Victoria Mateos, Teresa Paíno, Mercedes Garayoa, Enrique M Ocio (abstract)
S1579 – Preclinical Evaluation Of The New BCMAxCD3 Bispecific Antibody JNJ-957 For The Treatment Of Multiple Myeloma
9:00 AM - 9:15 AM
Kristine Frerichs, Marloes Broekmans, Jhon Marin Soto, Berris van Kessel, Amy Axel, Christopher Chiu, Homer Adams III, Sonja Zweegman, Tuna Mutis, Niels van de Donk (abstract)
| Session | Late Breaking Oral Session |
| Type | Oral Presentation Session |
| Time | Sunday June 17, 11:15 AM to 12:45 PM |
| Location | Room A1 |
| Chairs | M Muckenthaler and MV Mateos |
LB2606 – Elotuzumab Plus Pomalidomide / Dexamethasone (EPd) vs Pd For Treatment Of Relapsed / Refractory Multiple Myeloma (RRMM): Results From The Phase 2, Randomized Open-Label ELOQUENT-3 Study
12:30 PM - 12:45 PM
Meletios A Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, Philippe Moreau, Naoki Takezako, Mitsuo Hori, Xavier Leleu, Richard LeBlanc, Kenshi Suzuki, Marc S. Raab, Paul G. Richardson, Mihaela Popa McKiver, Ying-Ming Jou, Suresh G. Shelat, Michael Robbins, Brian Rafferty, Jesús San Miguel (abstract)
